Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi Puig

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Blood|June 4, 2026
Measurable residual disease in myeloma: a MyRiaD of findingsNoemi Puig
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2015
Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?Bruno Paiva, Noemi Puig, Ramón García-Sanz, et al.
Leukemia & Lymphoma|August 18, 2012
Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphomaNoemi Puig, Lisa Wang, Tara Seshadri, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2023
Disease Monitoring In Multiple MyelomaJens Hillengass, Tom Martin, Noemi Puig, et al.
Haematologica|December 20, 2011
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapyDiego Villa, Tara Seshadri, Noemi Puig, et al.
Journal of Hematology & Oncology|June 24, 2020
Measurable residual disease in multiple myeloma: ready for clinical practice?Leire Burgos, Noemi Puig, Maria-Teresa Cedena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Spontaneous remission in a patient with t(4;14) translocation multiple myelomaNoemi Puig, Suzanne Trudel, Jonathan J Keats, et al.
Nature Reviews. Clinical Oncology|April 8, 2025
Opportunities and challenges for MRD assessment in the clinical management of multiple myelomaBruno Paiva, Qian Shi, Noemi Puig, et al.
Haematologica|May 13, 2010
Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphomaNoemi Puig, Melania Pintilie, Tara Seshadri, et al.
Cancers|May 4, 2026
How Laboratory Innovations Are Shaping the Future of Multiple Myeloma CareJoana Caetano, Ana Marta Pires, Carlos Costa, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Blood|June 4, 2026
Measurable residual disease in myeloma: a MyRiaD of findingsNoemi Puig
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2015
Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?Bruno Paiva, Noemi Puig, Ramón García-Sanz, et al.
Leukemia & Lymphoma|August 18, 2012
Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphomaNoemi Puig, Lisa Wang, Tara Seshadri, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2023
Disease Monitoring In Multiple MyelomaJens Hillengass, Tom Martin, Noemi Puig, et al.
Haematologica|December 20, 2011
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapyDiego Villa, Tara Seshadri, Noemi Puig, et al.
Journal of Hematology & Oncology|June 24, 2020
Measurable residual disease in multiple myeloma: ready for clinical practice?Leire Burgos, Noemi Puig, Maria-Teresa Cedena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Spontaneous remission in a patient with t(4;14) translocation multiple myelomaNoemi Puig, Suzanne Trudel, Jonathan J Keats, et al.
Nature Reviews. Clinical Oncology|April 8, 2025
Opportunities and challenges for MRD assessment in the clinical management of multiple myelomaBruno Paiva, Qian Shi, Noemi Puig, et al.
Haematologica|May 13, 2010
Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphomaNoemi Puig, Melania Pintilie, Tara Seshadri, et al.
Cancers|May 4, 2026
How Laboratory Innovations Are Shaping the Future of Multiple Myeloma CareJoana Caetano, Ana Marta Pires, Carlos Costa, et al.
Pageof 9